Human papillomavirus (HPV) E6 proteins inhibit apoptosis in both p53-dependent and p53-independent manners. A key point in apoptosis is the regulation provided by the Bcl-2 family; and in dierentiating keratinocytes, in which HPV replicates, the Bak protein is highly expressed. We show that HPV-18 E6 will inhibit Bak-induced apoptosis and this is mediated by an interaction between the E6 and Bak proteins resulting in degradation of the Bak protein in vivo. We also show that Bak protein interacts with the ubiquitin ligase, E6AP, and that a mutant of Bak defective in E6AP binding is overexpressed in comparison with wild type. These studies suggest that Bak is probably the ®rst naturally occurring target of E6AP to be identi®ed.
Introduction
The mechanisms of apoptosis or programmed cell death have been shown to be present in the cells of a very wide variety of multicellular eukaryotes. In addition to its vital role in development, apoptosis plays an important part in the homeostasis of normal tissue by maintaining appropriate cell numbers (Jacobson et al., 1997, for review) . Thus it is particularly important in the immune system and as a method of escape from tumorigenesis. It has become clear in recent years that certain viruses have evolved strategies to circumvent apoptosis, and these tend to be associated with tumorigenesis. Among the best known of these strategies are the interactions of the SV40 TAg, Adenovirus E1B, and HPV E6 proteins with the cellular tumour suppressor protein, p53 (Lane and Crawford, 1979; Sarnow et al., 1982; Zantema et al., 1985; Werness et al., 1990) ; through which the viral proteins inactivate p53 function, albeit via dierent mechanisms (Schener et al., 1990; Bargonetti et al., 1992; Yew et al., 1994) .
It has been shown by a number of studies that the HPV E6 proteins derived from the tumour associated HPV types, such as HPV-16 and HPV-18, bind to p53 and inhibit p53's ability to bind to its DNA recognition sequence (Lechner and Laimins, 1994; Thomas et al., 1995 Thomas et al., , 1996b . In addition, complex formation between p53 and E6 is enhanced in the presence of an additional, 100 kd cellular protein, known as E6AP (Huibregtse et al., 1991 . E6AP is a ubiquitin protein ligase which is directed towards p53 by E6, the consequence of which is ubiquitinmediated degradation of the p53 protein (Schener et al., , 1994 (Schener et al., , 1995 . By preventing the accumulation of p53 in the cell, HPV is able to overcome its growth arrest and apoptosis-inducing functions (Thomas et al., 1996a) . However, in the absence of E6, E6AP does not recognise p53 to any signi®cant degree (Huibregtse et al., 1991) , which suggests that the natural cellular target(s) of E6AP remain to be identi®ed.
Recent work using transgenic mice expressing HPV-16 E6 in the ocular lens (Pan and Griep, 1995) con®rmed that E6 prevented apoptosis in vivo; furthermore, in mice which were also null for p53 HPV-16 E6 was still able to prevent the induction of apoptosis. It has also been shown that E6 will inhibit drug induced apoptosis in cells lacking p53 (Steller et al., 1996) . These studies have demonstrated that the E6 protein of oncogenic HPV types is able to prevent the apoptosis induced by both p53-dependent and p53-independent pathways.
An important point in the apoptosis pathway, downstream of the initial signalling, is the Judgement phase which forms a second major controlling point, either ameliorating or reinforcing upstream signals before the irrevocable entry into the apoptotic process (Reed, 1994; Nagata, 1997 , for reviews). The Adenovirus E1B 19k protein has been shown to inhibit apoptosis at this point in the apoptotic pathway by interacting with several proapoptotic proteins belonging to the bcl-2 family, including Bak and Bax (Farrow et al., 1995; Han et al., 1996) . Indeed, the Adenovirus E1B 19k protein has been shown to be functionally equivalent to the cellular antiapoptotic proteins Bcl-2 and Bcl-XL (Huang et al., 1997) . It seemed likely that interference at this point in the apoptotic pathway could also provide an explanation for the p53-independent anti-apoptotic activity of the HPV E6 proteins. HPV is a strictly epitheliotropic virus which replicates in dierentiating keratinocytes and it has recently been shown that the proapoptotic protein Bak is expressed at high levels in the upper epithelial layers (Krajewski et al., 1996) . We therefore initiated a series of studies to investigate whether the HPV-18 E6 protein could in any way modulate the death-inducing activity of Bak. Using two cell lines which are null for p53 (Saos-2 and mouse 10(1)) we show that HPV-18 E6 signi®cantly increases cell survival following the transfection of a Bak-expressing plasmid. Using Annexin V binding as a marker of apoptosis, we show that transfection of a Bakexpressing plasmid results in an increase in Annexin V binding compared with control cells, and that this binding is markedly reduced in cells co-transfected with an HPV-18 E6 expressing plasmid. We also demonstrate that HPV-18 E6 forms a protein complex with Bak in vitro and, further, will label Bak as a target for degradation in vivo. In addition, we demonstrate that Bak will complex with E6AP in the absence of E6 and that mutants of Bak unable to bind E6AP are dramatically overexpressed compared with wild type protein. Finally, inhibition of proteasome activity produces a signi®cant increase in the level of Bak protein expression. These results indicate that Bak may represent a natural target of the ubiquitin ligase, E6AP and that E6 stimulates the ubiquitin-mediated degradation of Bak through its interaction with Bak and E6AP.
Results

HPV-18 E6 can protect p53-null cells from Bak-induced apoptosis
Studies performed with HPV-16 E6 transgenic mice had indicated that E6 could down-regulate both p53-dependent and p53-independent apoptosis (Pan and Griep, 1995) . Considering the frequent conservation of function between proteins derived from dierent DNA tumour viruses and the high level of Bak expression in dierentiating keratinocytes, we decided to look at the action of E6 upon apoptosis induced by Bak.
In order to determine the eect of HPV-18 E6 upon non-p53 related apoptosis, we performed a series of cell survival assays similar to those reported previously (Chittenden et al., 1995b) , except that the cells used in these experiments were p53-null mouse 10(1) cells and human Saos-2 cells which lack both p53 and pRb. The cells were transfected with pCD:Bak-HA, either in the presence or absence of pCD:HPV-18E6. All transfections also included the pCH110 plasmid, expressing bgalactosidase. After 24 h the cells were ®xed and stained for LacZ expression and the blue cells were counted and scored as either dead or alive by morphological criteria. The collated results of at least ®ve separate transfections are shown in Figure 1 . It can be seen that, as would be expected, the expression of Bak in these cells signi®cantly reduces cell survival in a manner similar to that reported previously in Rat-1 cells (Chittenden et al., 1995b) . However, it can also be seen that the co-expression of HPV-18 E6 signi®cantly increases the level of cell survival in both cell lines. The mean numbers of dead cells are shown in Table 1 : the co-transfection of 18E6 with Bak reduces the number of dead cells to approximately half the number seen upon transfection of Bak alone. The transfection of HPV-18 E6 alone gives results indistinguishable from the transfection of vector alone (data not shown). Since there is no p53 in either of these cell lines, these results are a further indication that E6 has p53-independent anti-apoptotic activity. More signi®cantly however, these results show that E6 can inhibit the activity of the proapoptotic protein, Bak.
HPV-18 E6 protein interacts with Bak in vitro
Having shown that HPV-18 E6 can counteract the eect of Bak in vivo, we were then interested in determining whether this was through a direct interaction between E6 and Bak, analogous to that between the Adenovirus E1B 19k protein and Bak (Farrow et al., 1995; Huang et al., 1997) , or whether the eects of E6 were being mediated downstream of Bak. In order to do this we proceeded to investigate whether E6 could interact with Bak protein in vitro. We ®rst performed a co-immunoprecipitation assay using radio-labelled proteins translated in vitro. Equal amounts of Bak and of HPV-18 E6 were mixed together at 48C for 45 min and then anti-HA antibody (Boehringer ± Mannheim) was added for a further 45 min. HA-Bak alone and 18E6 alone were also incubated with the anti-HA antibody. As a positive control we performed a parallel co-immunoprecipitation assay with HPV-18 E6 and p53 using the anti-p53 antibody pAb1801 (Banks et al., 1986) . After incubation with Protein A-sepharose and extensive washing, the precipitated proteins were analysed by SDS ± PAGE and autoradiography. Figure 2a shows that HPV-18 E6 is co-precipitated by the anti-HA antibody only in the presence of Bak. In order to verify this immunoprecipitation assay and to obtain more quantitative data we investigated the ability of in vitro-translated Bak protein to bind to a GST ± 18E6 fusion protein. Bak was translated in vitro, as before, and incubated with the GST or GST ± 18E6 fusion protein. The resins were then washed extensively with PBS/0.5% NP40 and the remaining bound protein was detected by SDS ± PAGE and autoradiography. It can be seen in Figure 2b that, as expected, the E6 binds strongly to its homologous GST-fusion protein but not to GST alone (Pim et al., 1997) . It is clear that Bak also binds strongly to GST ± 18E6 fusion protein but not to the GST alone. In the lower panel the Coomassie stained gel is shown, demonstrating equal loading of GST or GST fusion protein. This assay was repeated at least ®ve times and was quantitated by scanning with a PhosphorImager: the collated results of these assays are shown in Table  2 . These results suggest that the abrogation of Bak function by E6 is probably mediated by a strong physical interaction between the proteins and not by interference in the Bak signalling pathway.
HPV-18 E6 binds sequences in the carboxy terminal region of Bak
The Adenovirus E1B 19k protein has homology with the bcl-2 family and binds to Bak via BH1 and BH2 domains, forming an inactive heterodimer (Hanada et al., 1995; Huang et al., 1997) . However, E6 lacks these homologous regions so it seemed likely that its binding would be dierent. In order to determine the regions of Bak involved in binding E6, we repeated the GST fusion protein binding assay using wild type Bak and two mutants: DGDBak which has a deletion covering the major part of the BH3 domain (amino acids 82 ± 94) and which is apoptosis-defective, and DCBak which has a carboxy-terminal truncation (amino acids 191 ± 211) and is competent for induction of apoptosis in Rat-1 cells (Chittenden et al., 1995b) . Binding assays were performed as above and it can be seen in Figure  3a that the DC mutation completely abolishes the ability of Bak to bind to the GST ± 18E6 fusion protein. The binding of DGDBak, is reduced but is nonetheless detectable. Since the BH3 domain is required for homodimerisation (Zha et al., 1996) , the DGD mutant cannot form homodimers and this result suggests that Bak can bind E6 as a monomer. Indeed, the approximately 50% reduction in binding seen with the DGD mutant compared with the wild type Bak is probably a re¯ection of this. We were then interested in identifying the region of E6 responsible for binding Bak, since in the case of the HPV-18 E6/p53 interaction multiple regions of the E6 protein seem to be involved (Pim et al., 1994) . To do this we compared Bak's binding to E6-GST with its binding to two truncated E6 fusion proteins. E6*-GST is an alternatively spliced E6 containing the ®rst 43 amino acids and E6CT ± GST contains the carboxy terminal half of E6 (amino acids 89 ± 158). The results of this assay can be seen in Figure 3b where it is clear that the interaction between E6 and Bak occurs through sequences in the C-terminal half of the HPV-18 E6 protein.
Since the two proteins bind through sequences in their carboxy terminal regions, the E6 abrogation of Bak function seen in Figure 1 seems unlikely to occur by the masking of the BH3 domain, as seen in the antiapoptotic heterodimers formed between members of the bcl-2 family. Therefore, inhibition of Bak function by E6 would appear to be through an alternative mechanism.
HPV-18 E6-mediated degradation of Bak in vitro and in vivo
The best known interaction of E6 with a cellular protein is its labelling of p53 as a target for ubiquitin-mediated degradation (Schener et al., 1990) . Indeed, this is one of the principal means by which E6 can inhibit the function of an abundant protein, since E6 is normally expressed at very low levels Banks et al., 1987) . It seemed possible that E6 might also use this method for abrogating the normal function of Bak. In order to investigate this possibility we performed a series of in vitro degradation assays analogous to those described for E6 and p53 (Pim et al., 1994; Thomas et al., 1995) . HPV-18 E6 and Bak were translated in vitro and were incubated together at 308C for 0, 30 or 60 min. As a positive control for the assay, HPV-18 E6 and p53 were also included and the results obtained are shown in Figure 4a . It can be seen that while p53 is almost completely degraded in the period of this assay there is only a modest reduction in Bak levels over the same time. These results might indicate that signalling for degradation is not the method by which E6 abrogates Bak function. However, some caution is necessary in view of reports (Foster et al., 1994; Crook et al., 1996; Gardiol and Banks, 1998) which have indicated that E6 mutants that are defective in their ability to label p53 for degradation in vitro are nonetheless functional in vivo. Hence the in vitro degradation assay is not necessarily an accurate re¯ection of the eects in vivo. We therefore performed a series of in vivo degradation assays. Saos-2 cells were transiently transfected with HA-tagged wt Bak, together with increasing amounts of pCD:HPV-18 E6. After 24 h the cells were harvested and the extracts were assayed for total protein content. Equalized samples of each extract were then analyzed for Bak protein levels by SDS ± PAGE and Western blotting using anti-HA monoclonal antibody. The results obtained are shown in Figure 4b where it can be seen that the presence of increasing amounts of HPV-18 E6 causes a reduction in the amount of Bak protein detected. This result suggests that HPV-18 E6 can indeed label Bak as a target for degradation in vivo.
Having identi®ed the region of Bak which binds to HPV-18 E6, we were interested in determining whether the inability of E6 to bind Bak would be re¯ected by an inability to label Bak as a target for degradation in vivo. The levels of protein expression in Saos-2 cells following transient transfection are quite low; therefore we proceeded to investigate the ability of HPV-18 E6 to direct the degradation of wild type Bak and the mutant Bak proteins in human 293 cells, which are more readily transfected than Saos-2 cells. The results of this assay are shown in Figure 4c and it is clear that The in vitro translated radiolabelled Bak proteins were bound to the indicated GST fusion proteins (E6* consists of amino acids 1 ± 43 and E6CT consists of amino acids 89 ± 158 of the E6 protein) and after extensive washing the bound proteins were determined by PAGE and autoradiography. The percentage of the input protein retained is also shown the presence of increasing concentrations of HPV-18 E6 causes the degradation of wild type Bak in 293 cells. It can also be seen that DGDBak is susceptible to E6-mediated degradation but that DCBak, which we have shown does not interact with E6, is completely resistant to E6-induced degradation. It is also interesting to note that the DCBak mutant is expressed at much higher levels than either the wild type Bak or the DGDBak mutant. It was possible that this was a re¯ection of increased transfection eciency, but co-transfecting a pCH110 b-galactosidase expression plasmid with the DGDBak and DCBak indicated identical levels of transfection eciency in the 293 cells (data not shown). It could also be argued that any eects of E6 on DCBak levels are masked by the high level of DCBak expression. Hence Figure 4d shows a shorter exposure of the same reprobed blot, within the linear range of the ®lm, and this con®rms the resistance of DCBak protein to HPV-18 E6-induced degradation.
These data indicate that HPV-18 E6 is able to induce the degradation of Bak in vivo. They also show that the mutant DGDBak which retains binding to E6 is also susceptible to in vivo degradation whereas mutant DCBak, which does not bind to E6, is not degraded by E6 in vivo. These results suggest that the interaction of Bak with HPV-18 E6 leads to Bak degradation in vivo. The high levels of DCBak seen in these assays is also remarkable and may suggest that the mechanism by which E6 induces Bak degradation corresponds to the mechanism by which Bak levels are normally regulated in the cell in the absence of E6.
HPV-18 E6 inhibits Bak-induced apoptosis in 293 cells
Having shown that the E6-induced degradation of Bak occurs in both Saos-2 cells and in 293 cells and that E6 increases cell survival following Bak transfection into Saos-2 cells, we were then interested in determining whether E6 could also aect Bak-induced apoptosis in 293 cells. We were also interested in investigating the apoptotic activity of the Bak mutants and the eects of E6 thereon. Although cell survival assays re¯ect the level of apoptosis we were interested in con®rming these results using a more direct approach. An early event in apoptosis is the exposure of phosphatidyl serine (PS) on the external surface of the cellular plasma membrane (Fadok et al., 1992) and this can be detected by the anity of PS for Annexin V (Thiagarajan and Tait, 1990; Martin et al., 1995) . We chose to investigate the levels of PS on the external surface of 293 cells which had been transfected either with empty vector, with Bak alone or with Bak plus HPV-18 E6. Twenty-four hours post-transfection the cells were harvested and incubated with FITCconjugated Annexin V using the Clontech ApoAlert kit. The cells were then subjected to FACS analysis and the results obtained are shown in Figure 5a and eects of E6 thereon. The assay was repeated using DGDBak and DCBak and the results obtained are shown in Figure 5b . It can be seen that wild type Bak again induced high levels of apoptosis, as measured by Annexin V binding, and this was signi®cantly reduced by co-expression of E6. Both the DGDBak and DCBak mutants produced only a slight increase in the numbers of 293 cells binding Annexin V and this was equally reduced by E6. This was somewhat surprising since, although DGDBak is known to be defective for apoptosis, DCBak had been shown to possess close to wild type levels of apoptotic activity in Rat-1 cells (Chittenden et al., 1995b) . These results suggest either a dierence between cell survival assays and Annexin V binding as measures of apoptosis or, alternatively, raises the possibility that dierent cell types dier in the way they respond to DCBak in the induction of apoptosis. To investigate this possibility further we repeated the cell survival assays in Saos-2 cells using both the wild type and the Bak mutants together with E6. The results obtained are shown in Figure 5c . It is clear from these assays that DGDBak has little eect on cell survival and this is consistent with previous reports. The DCBak mutant, however, does reduce cell survival but clearly not to the same degree as wild type Bak. This result is interesting in that it shows that cell survival and Annexin V-binding assays are not necessarily measuring the same parameter. It also supports the notion that dierences in cell types are important in the ability of DCBak to induce apoptosis. Since, by analogy with other bcl-2 family proteins, the C-terminus of Bak probably contains a membranelocalization domain (Tanaka et al., 1993) , this implies that Rat-1 cells, but not Saos-2 cells, are susceptible to non membrane-bound Bak. Studies using Bcl-2 mutants have also shown that there are spatially distinct apoptosis pathways in dierent cell types (Zhu et al., 1996) . It is also clear from these results that, while E6 can signi®cantly increase cell survival following wild type Bak transfection, it has no eect on cells transfected with the DCBak mutant, consistent with its being unable to interact with DCBak protein.
The ubiquitin ligase, E6AP, and HPV-18 E6 both bind to the carboxy terminal region of the Bak protein HPV-18 E6 induces the degradation of p53 through the ubiquitin pathway by its simultaneous interaction with p53 and a component of the cellular ubiquitin pathway known as E6AP (Huibregtse et al., 1991) . It seemed possible, therefore, that E6AP might also be involved in the E6-induced degradation of Bak. To investigate this possibility, we were ®rst interested in determining whether there was an interaction between Bak and E6AP. Therefore we performed a binding assay in vitro using a GST ± E6AP fusion protein and in vitro translated proteins as before. The results are shown in Figure 6a where it can be seen that, as expected, the HPV-18 E6 positive control binds strongly to GST ± E6AP fusion protein. It is also clear that the wild type Bak protein binds to a high degree to the GST ± E6AP. The DGDBak mutant also binds to E6AP, albeit less strongly than wild type, whereas the DCBak mutant is defective in E6AP-binding. These results suggest that there is strong interaction between E6AP and Bak, through a region of Bak close to that which binds E6.
In addition, mutant DCBak which is highly overexpressed in vivo fails to bind E6AP in vitro. This supports the hypothesis that Bak levels may normally be regulated by interaction with E6AP. Having shown that Bak will bind to E6AP in the absence of E6, it was important to determine whether E6 can bind directly to Bak or whether the interaction is mediated by E6AP. To do this we performed a further GST fusion protein binding assay using Bak translated in wheatgerm extract, which is known to lack E6AP (Huibregtse et al., 1991 . Bak and HPV-18 E6 were incubated separately with GST ± 18E6 and GST ± E6AP, and with GST ± 16E7 and GST as negative controls. The results are shown in Figure 6b ; where, as expected, there is no signi®cant binding to GST-E7 nor to GST alone. However, it is clear that Bak will bind to GST ± 18E6 in the absence of E6AP, thus demonstrating that the interactions between Bak and E6 and between Bak and E6AP are independent of one another.
Having demonstrated that Bak will interact with E6AP in vitro we were then interested in determining a b Figure 6 Bak interacts with GST ± E6AP fusion protein in vitro. (a) In vitro translated radiolabelled wt Bak, DGDBak and DCBak were incubated with GST ± E6AP (left hand panel) or GST alone (right hand panel) and, following extensive washing, bound proteins determined by PAGE and autoradiography. HPV-18 E6 was included as a positive control and the percentage of the input protein retained is shown. (b) Bak will bind to GST ± 18E6 fusion protein in the absence of E6AP. Wheatgerm extract-translated Bak was incubated with GST ± 18E6, GST ± E6AP, GST-16E7 and GST alone. Wheatgerm extract-translated 18E6 was used as a positive control. The input Bak protein (L) and half the input 18E6 protein (0.56L) were also run on the gel and the percentage of input protein retained is shown whether we could detect this interaction in vivo. To do this, 293 cells were transfected with HA-tagged wild type Bak and mutant Bak expression plasmids. After 20 h the proteins were extracted and immunoprecipitated with an anti-HA antibody. The precipitates were then analysed for the presence of co-precipitated E6AP by Western blotting using an anti-E6AP polyclonal antibody. The results obtained are shown in Figure 7a . It can clearly be seen that the wild type Bak and DGDBak, both of which are susceptible to degradation in vivo, can co-precipitate E6AP from a 293 cell extract while the DCBak which is resistant to degradation in vivo, does not co-precipitate E6AP. In the Western blot analysis of the crude 293 extract it is clear that the E6AP antibody recognises two proteins, one migrating at 95 kd which corresponds to E6AP; and one, of unknown identity, migrating at 150 kd. Signi®cantly, only the 95 kd E6AP protein is coprecipitated with Bak or DGDBak, further demonstrating the speci®city of the assay. Figure 7b shows a Western blot analysis of the levels of Bak proteins in the extracts used for immunoprecipitation. Aliquots corresponding to 3.3% (wild type Bak and DGDBak) or 0.67% (DCBak) of the total extract were separated by SDS ± PAGE and analysed by Western blotting with anti-HA antibody. Although there are considerably lower levels of wild type Bak than of DGDBak, they nonetheless coprecipitate similar levels of E6AP, and this is consistent with their in vitro anities for E6AP. More interestingly, this assay again demonstrates the massive overexpression of DCBak compared with wild type Bak and the DGDBak mutant. Figure 7c shows a control immunoprecipitation of wild type Bak, DGDBak and DCBak with anti HA antibody to demonstrate that all three proteins are recognized equally by the antibody.
Since E6AP is a ubiquitin ligase, the degradation of Bak is likely to occur through the ubiquitin pathway. Upon labelling with ubiquitin, proteins are rapidly degraded by the proteasome complex (Goldberg, 1992; Hershko and Ciechanover, 1992; Rechsteiner et al., 1993) . To con®rm that this is, indeed, the route by which Bak is degraded in vivo we decided to look at the levels of Bak in cells treated with inhibitors of proteasome activity. Three cell lines, HeLa, CaSKi and HT1080 were incubated in the presence or absence of N-acetyl-Leu-Leu-Norleucinal, which inhibits proteasome activity (Rock et al., 1994) . Two hours later the cells were harvested and proteins were extracted, as before; the proteins were analysed by Western blotting using an anti-Bak polyclonal antibody (Santa Cruz). Extracts from cells transfected with DGDBak and DCBak were used as a positive control for the protein and the results are shown in Figure 8a . In the absence of N-acetyl-Leu-LeuNorleucinal Bak levels are low in all three cell lines; however, upon inhibition of the proteasome, increased Bak protein levels are seen in HeLa and CaSKi cells. Both of these cell lines express E6 (HPV-18 E6 and HPV-16 E6, respectively) and these data provide additional evidence to suggest that E6 is able to stimulate the degradation of Bak via the proteasome. In HT1080 cells, which do not contain any HPV sequences, no increase in Bak levels is seen. Whether this is a re¯ection of the cell type, a reduced susceptibility of Bak to proteasome degradation in these cells or limitations of Bak detection with these antibodies remains to be determined. Therefore, to address the question of whether Bak can be degraded via the proteasome in the absence of E6, 293 cells were transfected with wild type or mutant Bak and, after overnight growth, were incubated for 90 min, 3 h or 18 h with the proteasome inhibitor N-acetyl-Leu-Leu-Norleucinal (at 50 mM ®nal concentration) (Rock et al., 1994) , prior to harvesting. The proteins were extracted as before and analysed by Western blot with anti-HA antibody; the results are shown in Figure 8b . It can be seen that the levels of wild type Bak increase upon treatment with proteasome inhibitor, as do the levels of DGDBak, but that the levels of DCBak remain relatively constant throughout. Since we have shown that wild type Bak and DGDBak can bind E6AP and DCBak cannot, this provides strong additional evidence for the suggestion that Bak levels are normally controlled by E6AP-mediated degradation through the proteasome. Even upon proteasome inhibition the levels of wild type Bak are very low which re¯ects the lethal eect of Bak upon any cell; higher levels of DGDBak are seen, re¯ecting the fact that accumulation of the DGDBak protein does not lead to apoptosis. Taken together, these results argue strongly that E6AP and Bak interact in the cell and, further, that this might represent the method by which Bak levels are normally regulated. Since the interaction between Bak and E6AP does not require the presence of HPV-18 E6, Bak may therefore represent the ®rst natural target of E6AP to be identi®ed.
Discussion
In the study presented here we have shown that HPV-18 E6 can abrogate the apoptosis induced by Bak in a p53-independent manner. We have demonstrated, by immuno-precipitation and by the use of GST fusion proteins in binding assays, that the two proteins will interact directly in vitro. Furthermore, we have mapped the sites of interaction to the C-terminal half of E6 and to the C-terminal 21 amino acid residues of Bak. We have also shown that E6-induced degradation of Bak occurs in vivo in both Saos-2 and 293 cells and that the degradation of Bak most probably occurs through its interaction with E6AP. These studies strongly support the hypothesis that Bak is a naturally occurring target of E6AP.
The replication of HPV occurs in dierentiating keratinocytes in the upper layers of the epidermis. Like many small DNA viruses, the virus does not encode its own DNA replication machinery but instead depends upon that of the cell. It is therefore clear that it is to the advantage of the virus to encourage DNA replication and to prevent growth-arrest. The response of a healthy cell to inappropriate DNA replication is apoptosis; therefore the virus has to walk a physiological tightrope, balancing the promotion of DNA replication with the suppression of apoptosis. E6 can partially prevent apoptosis by the labelling of p53 as a target for degradation via the ubiquitin pathway, through its interaction with the ubiquitin ligase E6AP (Schener et al., 1990) . However, p53 is not the only protein which signals the induction of apoptosis and E6 can also interfere with p53-independent apoptosis (Pan and Griep, 1995) . Since the bcl-2 family forms an important group of apoptosis controlling proteins, and by analogy with the adenovirus E1B 19k protein, it seemed probable that E6 might interfere with the correct function of one or more of the proapoptotic members of the family. Of this group of proapoptotic proteins, Bak seemed to be the most appropriate for investigation since it is highly expressed in the upper layers of terminally dierentiating epithelium which also corresponds to the site of papillomavirus replication. Both pro-and anti-apoptotic members of the bcl-2 family are thought to be pore-forming proteins, located in the nuclear, endoplasmic reticular and mitochondrial membranes (Chen-Leavy and Cleary, 1990; Hockenbery, et al., 1990; Krajewski et al., 1996) . HPV E6 proteins, although frequently found in the nucleus, have also been localized to non-nuclear membranes (Grossman et al., 1989; Kanda et al., 1991; Chen et al., 1995; Sherman and Schlegel, 1996) ; thus Bak and HPV-18 E6 have been found in the same subcellular locations.
Using two dierent markers of apoptosis, cell survival assays and Annexin V binding, we have shown that HPV-18 E6 markedly inhibits Bak-induced apoptosis in three dierent cell types, two of which are null for p53, thus demonstrating that E6's inhibition of Bak-induced apoptosis is p53-independent. Since E6 has no inherent growth-stimulatory activity in p53-null 10(1) cells or in Saos-2 cells (Pim et al., 1997) it is unlikely that this is an explanation for the increased cell survival, rather it represents an intrinsic antiapoptotic activity of HPV-18 E6. We then proceeded to investigate how this activity of E6 might be mediated and have demonstrated a strong physical interaction between Bak and HPV-18 E6 in vitro. Mutational analysis of both E6 and Bak identi®ed sequences within the carboxy terminal regions of both proteins as being important for the interaction. The most well-de®ned activity of E6 is its interaction with the cellular tumour suppressor protein, p53. HPV-18 E6 interacts with both p53 and a cellular ubiquitin ligase, E6AP, and as a consequence labels p53 as a target for ubiquitin-mediated degradation. It was therefore obvious to investigate whether E6 could induce the degradation of the Bak protein and, further, whether E6AP was involved. In vitro assays demonstrated that E6 had only a modest capacity to induce Bak degradation. However, when the assays were repeated in vivo a very clear reduction in Bak protein levels was observed in cells containing E6 compared with those cells containing vector alone. The speci®city of these degradation reactions was con®rmed by inclusion of the mutant DCBak, which cannot bind to E6 in vitro. In this case, no degradation of this mutant Bak protein was observed. These results raised two important questions: ®rst, why was degradation in vitro inecient compared with degradation in vivo? and second, how was the degradation of Bak being brought about? The ®rst point is resolved by a number of recent studies with mutant p53 and E6 proteins. Although a large number of in vitro degradation assays have been done using mutants of both p53 and E6 it is only recently that these assays have been performed in vivo. In at least three instances (Foster et al., 1994 , Crook et al., 1996 , Gardiol and Banks, 1998 , there are clear examples of mutants of both p53 or E6 which are either resistant to, or incapable of inducing, degradation in vitro, but which are nonetheless susceptible to, or active in, degradation in vivo. This has indicated that the behaviour of proteins in in vitro assays does not necessarily re¯ect their in vivo activities; this would also appear, from the results presented here, to be true for the E6-induced degradation of Bak. The second, and more important, question refers to how E6 might be inducing Bak degradation. A clue to this came from the DCBak mutant. This protein does not bind E6, is resistant to E6-induced degradation, and is expressed at very high levels in vivo compared with wild type Bak protein. This suggested that the mechanism through which E6 targets Bak for degradation might also be used by the cell under normal circumstances. HPV-18 E6-induced degradation of p53 occurs through its interaction with E6AP and we therefore investigated the role of this protein in the E6 Bak interaction. To our surprise, we found that E6AP could bind Bak strongly in the absence of E6 both in vitro and in vivo. Most interestingly, E6AP also binds to the same carboxy terminal region of the Bak protein as E6. Therefore the increased stability of the DCBak mutant probably correlates with a lack of E6AP binding. These results therefore raise the exciting possibility that Bak is normally regulated by E6AP in the absence of E6. This hypothesis is strengthened by the ®nding that in the presence of proteasome inhibitors the levels of Bak protein in the cell increase, as do the levels of the DGD mutant but not the DC mutant. It is clear that in E6-containing cell lines the inhibition of the proteasome results in increased levels of endogenous Bak protein. This leaves the ®nal question of how E6 stimulates Bak degradation. We know that both E6 and E6AP bind to the carboxy terminal region of the Bak molecule and their binding does not appear to be mutually exclusive (data not shown). We also know that the carboxy terminal half of HPV-18 E6 binds to Bak, but that the amino terminal region of HPV-18 E6 binds to E6AP (Pim et al., 1997) . Therefore E6 can potentially bind both E6AP and Bak simultaneously. Studies are now in progress to determine whether E6 increases the anity of E6AP for Bak or, alternatively, stimulates the ubiquitination of Bak through its interaction with E6AP.
Recent studies have shown that point mutations in E6AP are associated with Angelman syndrome (Kishino et al., 1997; Matsuura et al., 1997) and indicate that the syndrome may be associated with abnormality in ubiquitin-mediated degradation during brain development. Given the importance of apoptosis in development and the fact that Bak is found at high levels in the frontal cortex (Krajewski et al., 1996) , it is tempting to speculate that the association between E6AP and Bak demonstrated here may partly explain the biochemical basis of a serious developmental disease.
In summary, we have de®ned an alternative mechanism through which HPV-18 E6 can inhibit apoptosis, independent of its interaction with p53. This anti-apoptotic activity of E6 is mediated through an association with the proapoptotic protein Bak which E6 inactivates by increasing the level of Bak degradation. This degradation most probably occurs through ubiquitination by the E6AP protein and Bak may represent one of the normal cellular targets of E6AP in the absence of HPV infection.
Materials and methods
Cells and transfections
The cells used for transfections were murine p53-null 10(1) cells, human Saos-2 cells and human 293 cells. HeLa, CaSKi and HT1080 cells were used for analysis of endogenous Bak levels. They were maintained in DMEM supplemented with 10% foetal calf serum. The cells were transfected by the standard calcium phosphate precipitation procedure, as described previously Pim et al., 1994) , all transfections being equalized with vector DNA. The eciency of transfection was monitored by the transfection of the pCH110 plasmid into parallel dishes of cells and their subsequent staining for Lac Z expression. Saos-2 and 10(1) cells were similarly stained in the cell survival assays, only those cells or apoptotic bodies stained blue were counted.
DNA constructs
For in vitro translation the HPV E6 DNA sequences were cloned into pSp64 as previously described (Pim et al., 1994) . The Bak sequences were cloned into pCDNA3 (Chittenden et al., 1995a, b) and were used thus for both in vivo and in vitro assays. The E6AP used was the 76 k form of the protein and was kindly provided by Martin Schener (Huibregste et al., 1993) , and was cloned into pSP64 for in vitro translation. For production of all the GST fusion proteins the sequences were cloned into pGEX2.
All of the Bak constructs had an N-terminal HA tag for ease of detection.
In vitro translation
All proteins were translated in vitro using the Promega TNT kit according to the manufacturers instructions. All
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Expression of GST fusion proteins
HPV-18 E6 was cloned into pGEX.2 and transfected into DH5 (rec7) cells. A 50 ml aliquot was grown at 378C overnight in Luria broth (LB) and then passaged into 500 ml LB. After growth for 1 h at 378C protein expression was induced by addition of IPTG (isopropylthiogalactopyranoside), to a ®nal concentration of 1 mM. After incubation for 3 h at 378C the cells were pelleted and resuspended in 5 ml PBS, 0.5% Triton X-100, then sonicated on dry ice for 30 s. The cell debris was removed by centrifugation and the supernatant incubated at 48C overnight with Glutathione conjugated agarose (Sigma) on a rotating wheel.
GST fusion protein binding assays
The fusion proteins conjugated to Glutathione agarose were washed for 4615 min with PBS, 0.5% Triton X-100 and 1615 min with PBS alone. A 10 ml sample was analysed for protein concentration by SDS ± PAGE and staining with Coomassie Brilliant Blue. The in vitro translated proteins were then incubated with aliquots of the resins, equalised for GST fusion protein concentration. Incubations were performed on ice with shaking; after 1 h the aliquots of resin were washed 46 with PBS, 0.5% Nonidet-P40 and the bound proteins were then analysed by SDS ± PAGE and autoradiography.
Western blot analyses
The cells to be analysed were washed 26 with PBS and drained thoroughly. Each 100 mm tissue culture dish was scraped into 150 ml of E1A buer (50 mM HEPES, 250 mM NaCl, 0.1% Nonidet-P40, 1% Aprotinin). The cellular debris was spun out and the protein concentration of the supernatant determined using the Biorad Protein Assay reagent. Samples were equalized for protein concentration and were then separated by SDS ± PAGE; subsequently the proteins were transferred to nitrocellulose membrane by Western blotting. The blots were probed with speci®c antibodies, as speci®ed in the text and then developed using the Amersham ECL detection method, according to the manufacturer's instructions.
Detection of apoptosis by Annexin V binding
Two hundred and ninety-three cells were transfected with the required plasmids as described above. After 24 h the cells were washed and trypsinized as for normal passaging. They were then washed once in DMEM/10%FCS and once in PBS. The amount of apoptosis was then determined by incubating the cells with Annexin V-FITC using the ApoAlert kit (Clontech) according to the manufacturers instructions. The cells were then analysed using a FACSCalibur¯uorescence-activated cell sorter (Becton Dickinson).
